Alira Health
Alira Health Launches SpherePX™, a Next-Generation Technology Platform to Advance Real-World Evidence
Alira Health Launches SpherePX™, a Next-Generation Technology Platform to Advance Real-World Evidence
FRAMINGHAM, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global healthcare consulting and research organization, announces the global launch of its innovative technology platform SpherePX, designed to drive real-world evidence (RWE) collection and elevate patient engagement and retention. This platform empowers organizations to seamlessly manage Phase 4 studies and patient registries, including post-authorization safety studies (PASS), effectiveness assessments, and comparative studies.
To further support its expanding technology offerings, Alira Health has appointed Ifti Alli as Vice President of Digital Solutions. Ifti, who brings experience from his work at Experian Health, Medidata, and other health-tech startups, will play a pivotal role in driving Alira Health’s technology solutions to market more broadly.
"SpherePX’s ability to orchestrate patient journeys represents a game-changing innovation for the life sciences industry," says Alira Health’s Chief Strategy Officer, Piergiulio Lauriano. "With its advanced patient-centric design, modular flexibility, and seamless interoperability, the platform enables our partners to generate robust real-world evidence. Under Ifti’s leadership, we are excited to take our technology to the next level."
Key Benefits:
- Patient Centricity: Offers a hyper-configurable orchestrator with an intimate understanding of the patient journey to build user-friendly workflows that enhance engagement and outcomes, minimizing setup time and maximizing patient focus.
- Flexibility: Fully modular offering tailored to minimize complexity and maximize speed, ensuring each solution meets specific client needs while providing immediate insights for faster, data-driven decisions.
- Enhanced Data Collection and Integration: Integrates data seamlessly from diverse sources, including EMRs, wearable devices, and other healthcare systems.
- Interoperability: Fits seamlessly into existing workflows, enabling effortless data exchange.
- Regulatory Compliance: Adheres to HIPAA, GDPR, and 21 CFR Part 11 standards.
A Vision for Patient-Enabled Healthcare
This innovative technology aligns with Alira Health’s mission of improving the lives of patients globally through innovation and collaboration. Its patient-enabled framework ensures that every study conducted not only meets the needs of stakeholders but also delivers measurable value to the patients who rely on these breakthroughs.
Availability
SpherePX is now available to pharmaceutical and medtech companies worldwide. For more information or to schedule a demonstration, please contact Ifti Alli at iftikar.alli@alirahealth.com or visit Alira Health’s website.
About Alira Health
Alira Health is a global healthcare consulting and research organization committed to making a positive impact on patients’ lives worldwide. We provide integrated consulting services across regulatory, market access, and commercial strategy, along with full-service clinical trial management and patient-centric evidence generation. By combining strategic guidance with practical execution, we empower life sciences companies with data-driven insights, ensuring successful outcomes and measurable impact across the healthcare ecosystem.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Financière de Tubize SA2.8.2025 08:00:00 CEST | Press release
Financière de Tubize - 2025 half-year financial report
DBV Technologies S.A.1.8.2025 22:05:00 CEST | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Mandalay Resources Corporation1.8.2025 21:12:01 CEST | Press release
Mandalay Obtains Final Order Approving Arrangement with Alkane
F. Hoffmann-La Roche Ltd1.8.2025 20:00:00 CEST | Press release
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
KBC Groep1.8.2025 18:10:00 CEST | Press release
KBC Group: KBC remains well-capitalised under 2025 EU-wide EBA stress test
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom